Logo image of DRTS

ALPHA TAU MEDICAL LTD (DRTS) Stock Price, Quote, News and Overview

NASDAQ:DRTS - Nasdaq - IL0011839383 - Common Stock - Currency: USD

2.73  +0.09 (+3.41%)

DRTS Quote, Performance and Key Statistics

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (4/29/2025, 3:23:13 PM)

2.73

+0.09 (+3.41%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High4.39
52 Week Low1.75
Market Cap191.37M
Shares70.10M
Float56.33M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-21 2025-05-21/amc
IPO03-08 2022-03-08


DRTS short term performance overview.The bars show the price performance of DRTS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

DRTS long term performance overview.The bars show the price performance of DRTS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of DRTS is 2.73 USD. In the past month the price increased by 3.13%. In the past year, price increased by 6.02%.

ALPHA TAU MEDICAL LTD / DRTS Daily stock chart

DRTS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.42 227.28B
ISRG INTUITIVE SURGICAL INC 67.49 184.73B
BSX BOSTON SCIENTIFIC CORP 38.1 152.15B
SYK STRYKER CORP 30.42 141.54B
MDT MEDTRONIC PLC 15.89 108.81B
BDX BECTON DICKINSON AND CO 14.86 59.37B
EW EDWARDS LIFESCIENCES CORP 29.33 44.84B
IDXX IDEXX LABORATORIES INC 38.88 35.44B
RMD RESMED INC 26.16 34.89B
GEHC GE HEALTHCARE TECHNOLOGY 15.22 31.28B
DXCM DEXCOM INC 43.2 27.95B
PHG KONINKLIJKE PHILIPS NVR- NY 15.96 23.55B

About DRTS

Company Profile

DRTS logo image Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.

Company Info

ALPHA TAU MEDICAL LTD

Kiryat Hamada 5

JERUSALEM IL

Employees: 121

Company Website: https://www.alphatau.com/

Investor Relations: https://www.alphatau.com/events

Phone: 97235774115

ALPHA TAU MEDICAL LTD / DRTS FAQ

What is the stock price of ALPHA TAU MEDICAL LTD today?

The current stock price of DRTS is 2.73 USD. The price increased by 3.41% in the last trading session.


What is the ticker symbol for ALPHA TAU MEDICAL LTD stock?

The exchange symbol of ALPHA TAU MEDICAL LTD is DRTS and it is listed on the Nasdaq exchange.


On which exchange is DRTS stock listed?

DRTS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALPHA TAU MEDICAL LTD stock?

10 analysts have analysed DRTS and the average price target is 6.63 USD. This implies a price increase of 142.86% is expected in the next year compared to the current price of 2.73. Check the ALPHA TAU MEDICAL LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALPHA TAU MEDICAL LTD worth?

ALPHA TAU MEDICAL LTD (DRTS) has a market capitalization of 191.37M USD. This makes DRTS a Micro Cap stock.


How many employees does ALPHA TAU MEDICAL LTD have?

ALPHA TAU MEDICAL LTD (DRTS) currently has 121 employees.


What are the support and resistance levels for ALPHA TAU MEDICAL LTD (DRTS) stock?

ALPHA TAU MEDICAL LTD (DRTS) has a support level at 2.64 and a resistance level at 2.65. Check the full technical report for a detailed analysis of DRTS support and resistance levels.


Should I buy ALPHA TAU MEDICAL LTD (DRTS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALPHA TAU MEDICAL LTD (DRTS) stock pay dividends?

DRTS does not pay a dividend.


When does ALPHA TAU MEDICAL LTD (DRTS) report earnings?

ALPHA TAU MEDICAL LTD (DRTS) will report earnings on 2025-05-21, after the market close.


What is the Price/Earnings (PE) ratio of ALPHA TAU MEDICAL LTD (DRTS)?

ALPHA TAU MEDICAL LTD (DRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).


What is the Short Interest ratio of ALPHA TAU MEDICAL LTD (DRTS) stock?

The outstanding short interest for ALPHA TAU MEDICAL LTD (DRTS) is 0.18% of its float. Check the ownership tab for more information on the DRTS short interest.


DRTS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to DRTS. When comparing the yearly performance of all stocks, DRTS is a bad performer in the overall market: 69.14% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DRTS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to DRTS. While DRTS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DRTS Financial Highlights

Over the last trailing twelve months DRTS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -7.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.83%
ROE -50.67%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-7.14%
Revenue 1Y (TTM)N/A

DRTS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to DRTS. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners1.89%
Ins Owners25.56%
Short Float %0.18%
Short Ratio2.18
Analysts
Analysts86
Price Target6.63 (142.86%)
EPS Next Y-15.15%
Revenue Next YearN/A